Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

BJU International

Volumn 91, Issue 7, 2003, Pages 608-612

  Duffield Lillico, A J ^a   Dalkin, B L ^a   Reid, M E ^b   Turnbull, B W ^c   Slate, E H ^d   Jacobs, E T ^a   Marshall, J R ^b   Clark, L C ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Cornell University   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemoprevention; Incidence; Prostate cancer; PSA; Risk; Selenium

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SELENIUM;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NUTRITION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK FACTOR; SKIN CARCINOMA; VITAMIN SUPPLEMENTATION;

BIOPSY; DIETARY SUPPLEMENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SELENIUM;

EID: 0038244793     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04167.x     Document Type: Article

References (22)

1. Clark LC, Combs GF Jr, Turnbull BW et al. for the Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 1996; 276: 1957-63
2. Clark LC, Dalkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730-4
3. Hoedemaeker RF, Vis AN, Van Der Kwast TH. Staging prostate cancer. Microsc Res Tech 2000; 51: 423-9
4. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-90
5. Schroder FH, van der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 1817-23
6. Maattanen L, Auvinen A, Stenman UH et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210-4
7. Brooks JD, Metter EJ, Chan DW et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001; 166: 2034-8
8. Yoshizawa K, Willett WC, Morris SJ et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998; 90: 1219-24
9. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomerkers Prev 2000; 9: 883-7
10. West DW, Slattery ML, Robison LM, French TK, Mahoney AW. Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors. Cancer Causes Control 1991; 2: 85-94
11. Willett WC, Polk BF, Morris JS et al. Prediagnostic serum selenium and risk of cancer. Lancet 1983; 2: 130-4
12. Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinal and the subsequent risk of cancer. Am J Epidemiol 1988; 128: 515-23
13. Helzlsouer KJ, Huang HY, Alberg AJ et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000; 92: 2018-23
14. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 1985; 130: 603-9
15. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000; 9: 1171-82
16. Jiang C, Wang Z, Ganther H, Lu J. Caspases as key executors of methyl selenium-induced a poptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001; 61: 3062-70
17. Kumaraswamy E, Malykh A, Korotkov KV et al. Structure-Expression Relationships of the 15-kDa Selenoprotein Gene. Possible role of the protein in cancer etiology. J Biol Chem 2000; 275: 35540-7
18. Maul JW. Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. Urology 2001; 57: 174-7
19. Cook NR, Stampfer MJ, Ma J et al. Betacarotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma. Cancer 1999; 86: 1783-92
20. Colditz GA. Selenium and cancer prevention. Promising results indicate further trials required. JAMA 1996; 276: 1984-5
21. Clark LC, Marshall JR. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer. Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urology 2001; 57: 185-7
22. Klein EA, Thompson IM, Lippman SM et al. SELECT. The next prostate cancer prevention trial. J Urol 2001; 166: 1311-5